A vaccine for lung adenocarcinoma in veterans
Part of Cancer clinical trials.
This study tests an experimental vaccine (called Labyrinthin) for veterans with a specific type of lung cancer (lung adenocarcinoma). The vaccine aims to help your immune system fight the cancer, and you'll also receive pembrolizumab (Keytruda), an immunotherapy drug. This may help if your cancer has stopped responding to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lung adenocarcinoma, a type of lung cancer.
- Your tumor must have a specific marker called labyrinthin (this is checked on a biopsy sample).
- You have already tried at least one type of immunotherapy (like pembrolizumab or similar), and your cancer either grew, didn't respond, or you had side effects that made you stop.
- You are able to receive pembrolizumab (Keytruda) as a treatment.
- You have no untreated or active brain metastases (if treated and stable, you may qualify).
- You are generally in good health (able to do light activity, and your organ function is within normal limits as shown by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies pembrolizumab (an immune-boosting cancer medicine) alone or with an added investigational UV1 vaccine in people with advanced non-small cell lung cancer. It aims to see whether adding the vaccine improves safety and effectiveness, especially in tumors with high PD-L1 levels.
This trial tests a personalized mRNA vaccine (made from your own tumor's genetic fingerprint) combined with an immunotherapy drug called adebrelimab. The goal is to see if this combination can help prevent lung cancer from coming back or slow its growth.
This trial tests a new treatment combining a dendritic cell vaccine (a type of immune therapy that trains your body to fight cancer) with additional immunotherapy drugs. It is for people with advanced lung cancer that has stopped responding to standard immunotherapy.
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
This trial tests a combination of a drug injected directly into the lung tumor and a systemic antibody treatment (likely immunotherapy) for advanced non-small cell lung cancer. It may help if you have a collapsed lung and your cancer has not responded to prior treatment.
This trial tests whether restarting immunotherapy along with chemotherapy and radiation can help veterans with stage III lung cancer that cannot be removed by surgery. It's for people whose tumors have a certain protein (PD-L1) and who haven't had these treatments before for advanced cancer.
Hear when a new Type and Grade of Toxicities, Demographic and Background Characteristics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.